Ulixertinib by BioMed Valley Discoveries for Neurofibromatoses Type I (Von Recklinghausen’s Disease): Likelihood of Approval

Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase I for Neurofibromatoses Type I (Von Recklinghausen’s Disease).

Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data

Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for up to three years experienced less cognitive decline than what’s

July 30, 2024

Study: Fewer Kids in the ED Means More Missed Diagnoses

Emergency departments (EDs) that saw fewer kids were more likely to have potentially delayed diagnoses for serious acute conditions in that population, a large retrospective

February 13, 2024

QuidelOrtho names ex-Abbott exec Brian Blaser as CEO

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Name: Brian Blaser New title: CEO, QuidelOrtho

May 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.